Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

- PMLiVE

FDA backs GBT’s sickle cell drug Oxbryta

Second new treatment for blood disorder to be approved this year

Teva Pharma logo

Teva among generic drugmakers hoping to settle US antitrust probe

A number of companies are accused of colluding on drug prices

- PMLiVE

Private equity firm backs Ferring gene therapy venture

Joint venture will focus on development of therapies for bladder cancer

AI: opportunities and barriers to improving healthcare

How AI is shaping the future of healthcare

Is competition the enemy of progress and collaboration the ally of success?

By Jessica Pacey, CEO, 67health

- PMLiVE

WHITE PAPER: Patient nonadherence – the $637bn paradox

What’s not changed for 50 years, kills 200,000 Europeans annually, costs pharma $637 billion and the NHS over £500 million a year? We’ll tell you.

IGNIFI

- PMLiVE

Novartis acquires The Medicines Company for $9.7bn following takeover rumours

MedCo's cholesterol lowering inclisiran main attraction in planned acquisition

- PMLiVE

Roche’s Tecentriq/Avastin combo improves survival in liver cancer

First regimen to achieve improved overall survival in ten years

- PMLiVE

Thousands of EU staffers have left NHS since 2016, says Lib Dems

Figures come from information provided by 50 NHS hospital trusts

- PMLiVE

Roche scores FDA priority review for risdiplam in SMA

Potential rival to Novartis’ Zolgensma and Biogen’s Spinraza

- PMLiVE

A snapshot of Microbiotica

PME talks to CEO Mike Romanos

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links